Business Context and Reporting Period
This Form 8-K is a Current Report filed by Ra Medical Systems, Inc. (the "Company") on December 1, 2022. The filing primarily addresses a joint press release with Catheter Precision, Inc. ("Catheter") and provides updates regarding a proposed stock-for-stock reverse merger transaction between the two entities.
Key Financial Metrics
This filing does not contain specific financial statements, revenue figures, profit margins, or cash flow data for the reporting period. It serves as a notification of a corporate event and a product milestone.
- Product Milestone: The VIVO® System has been utilized in more than 800 procedures across leading U.S. and European hospitals.
- Transaction Structure: Catheter is to become a wholly owned subsidiary of Ra Medical in a stock-for-stock reverse merger.
- Financial Data Reference: The filing directs investors to a prior Form 8-K filed on September 12, 2022, for Catheter's audited financial statements (ended Dec 31, 2021) and unaudited pro forma combined financial information.
Material Changes and Transaction Status
The primary material change is the advancement of the merger process and the commercial adoption of Catheter's technology.
- Merger Timeline: The transaction is expected to close before the end of 2022 or during the first quarter of 2023, subject to closing conditions.
- Shareholder Approval: The merger requires approval from the stockholders of both Ra Medical and Catheter Precision.
- Regulatory Filings: Ra Medical intends to file a Definitive Proxy Statement to solicit votes. Catheter Precision intends to furnish an information statement and consent solicitation to its stockholders.
Guidance, Outlook, and Risks
Management commentary focuses on the strategic benefits of combining the companies to focus on the cardiac electrophysiology market. The filing includes significant forward-looking statements and risk disclosures.
- Closing Conditions: The Merger Agreement includes conditions such as a minimum prevailing stock price for Ra Medical and a specific Net Cash amount at closing. If Ra Medical's stock price drops below certain levels, the merger consideration for Catheter stockholders may be adversely impacted.
- Capital Markets: Risks include the ability of the combined company to access capital markets to meet Net Cash requirements and maintain its listing on the NYSE American.
- External Risks: The filing highlights risks related to the COVID-19 pandemic, economic uncertainty, and potential delays in consummating the merger.
- Pro Forma Limitations: Unaudited pro forma financial information referenced in prior filings does not reflect potential cost savings or restructuring costs and is not intended to project future results.
Investor Verification Checklist
- Verify the status of the Definitive Proxy Statement and the Private Placement Memorandum/Joint Information Statement for detailed transaction terms.
- Review the September 12, 2022 Form 8-K for Catheter Precision's audited financial statements and unaudited pro forma combined financial information.
- Monitor Ra Medical's stock price relative to the minimum prevailing stock price condition required for the merger closing.
- Confirm the Net Cash requirements at closing and the company's current liquidity position to meet these obligations.
- Assess the 800+ procedures milestone for the VIVO® System as an indicator of market adoption and future revenue potential.